AVBP Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 122725 min ago

@ $21.16

Wydano: 14 vas. 2024 @ 22:35

Zwrot: -14.98%

Poprzedni sygnał: vas. 13 - 20:28

Poprzedni sygnał: Sprzedaż

Zwrot: -2.49 %

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	29 725.00
Średni wolumen	181 357
Kapitalizacja rynkowa	602.55M
Następna data zysków	( $0 ) 2024-06-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0810 (0.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	555 555	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	313 076	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	3 616 041	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Sell	4 761 903	Series B Preferred Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Sell	55 000 000	Series A Preferred Stock

INSIDER POWER
-74.77
Last 24 transactions
Buy: 9 226 636 \| Sell: 63 909 387

Wolumen Korelacja

Długi: 0.31 (neutral)

Krótki: 0.58 (weak)

Signal:(72.837) Neutral

ArriVent BioPharma, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ArriVent BioPharma, Inc. Korelacja - Waluta/Towar

0.44
( neutral )

0.55
( weak )

0.00
( neutral )

0.55
( weak )

-0.36
( neutral )

0.00
( neutral )

Financial Reports:

No articles found.

ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.